Physician profile
Constance Ediale
NPI 1720666886
$2,987.25
in general payments reported to CMS, 2019-2025
13 companies · $1,663 in 2025
The $1,663 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $150 · 2023: $199 · 2024: $976 · 2025: $1,663.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,838.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,837.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $627.39 | 2022-2025 | |
| Leo Pharma INC. | $434.60 | 2025 | Adbry, Anzupgo |
| Incyte Corporation | $427.88 | 2024-2025 | Opzelura |
| Boehringer Ingelheim Pharmaceuticals, INC. | $344.90 | 2022-2024 | Spevigo |
| Genzyme Corporation | $308.01 | 2025 | |
| Sun Pharmaceutical Industries INC. | $306.15 | 2025 | |
| Janssen Scientific Affairs, LLC | $207.05 | 2025 | Tremfya |
| Lilly USA, LLC | $130.85 | 2024 | Ebglyss, Taltz |
| Pfizer INC. | $56.49 | 2025 | |
| Janssen Biotech, INC. | $54.35 | 2025 | Tremfya |
| E.R. Squibb & Sons, L.L.C. | $34.58 | 2025 | Sotyktu |
| Novartis Pharmaceuticals Corporation | $28.64 | 2025 | |
| Lnhc, INC | $26.36 | 2025 | Zelsuvmi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Constance Ediale listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.